Wilson Therapeutics

Stockholm, Sweden Founded: 2012 • Age: 14 yrs Acquired By Alexion
De-coppering agents for Wilson disease treatment are developed.
Request Access

About Wilson Therapeutics

Wilson Therapeutics is a company based in Stockholm (Sweden) founded in 2012 was acquired by Alexion in April 2018.. Wilson Therapeutics has raised $40 million across 2 funding rounds from investors including Alexion, Abingworth and MVM Partners. Wilson Therapeutics operates in a competitive market with competitors including Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others.

  • Headquarter Stockholm, Sweden
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $40 M (USD)

    in 2 rounds

  • Latest Funding Round
    $29.73 M (USD), Post-IPO

    Dec 01, 2017

  • Investors
    Alexion

    & 3 more

  • Employee Count
    Employee Count
  • Acquired by
    Alexion

    (Apr 11, 2018)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Wilson Therapeutics

Wilson Therapeutics has successfully raised a total of $40M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $29.73 million completed in December 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Post-IPO — $29.7M
  • First Round

    (14 Apr 2014)

  • Investors Count 3
Date Amount Transaction Name Valuation Lead Investors Investors
Dec, 2017 Amount Post-IPO - Wilson Therapeutics Valuation

investors

Apr, 2014 Amount Series B - Wilson Therapeutics Valuation Abingworth , MVM
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Wilson Therapeutics

Wilson Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Alexion, Abingworth and MVM Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early stage venture capital firm investing in US
Founded Year Domain Location
Healthcare real estate solutions are provided by HealthCap since 1996.
Founded Year Domain Location
Private equity investments in healthcare companies are managed.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Wilson Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Wilson Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Wilson Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Wilson Therapeutics

Wilson Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, Gemini Therapeutics, BioMarin Pharmaceutical and Mirum Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
RNA interference-based therapeutics are developed for multiple disorders.
domain founded_year HQ Location
Therapeutics for rare and ultra-rare metabolic diseases are developed.
domain founded_year HQ Location
Developer of precision therapeutics for dry AMD and rare genetic diseases
domain founded_year HQ Location
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
domain founded_year HQ Location
Small molecule therapeutics are developed for rare diseases treatment.
domain founded_year HQ Location
Developer of gene therapies for rare genetic diseases
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Wilson Therapeutics

Frequently Asked Questions about Wilson Therapeutics

When was Wilson Therapeutics founded?

Wilson Therapeutics was founded in 2012 and raised its 1st funding round 2 years after it was founded.

Where is Wilson Therapeutics located?

Wilson Therapeutics is headquartered in Stockholm, Sweden.

Is Wilson Therapeutics a funded company?

Wilson Therapeutics is a funded company, having raised a total of $40M across 2 funding rounds to date. The company's 1st funding round was a Series B of $40M, raised on Apr 14, 2014.

What does Wilson Therapeutics do?

Wilson Therapeutics was founded in 2012 in Stockholm, Sweden, within the biotechnology sector. Focus is placed on treatments for Wilson Disease, a rare genetic disorder involving copper accumulation in tissues. The lead product, WTX101, is advanced as a clinical-stage de-coppering agent. High-stability complexes with copper and proteins are formed by WTX101, which are excreted primarily via bile to restore impaired copper elimination in affected patients.

Who are the top competitors of Wilson Therapeutics?

Wilson Therapeutics's top competitors include Alnylam, BioMarin Pharmaceutical and Pharvaris.

Who are Wilson Therapeutics's investors?

Wilson Therapeutics has 4 investors. Key investors include Alexion, Abingworth, MVM Partners, and HealthCap.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available